Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Free Report) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 452,800 shares, a growth of 112.2% from the February 13th total of 213,400 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 358,400 shares, the short-interest ratio is presently 1.3 days.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Acurx Pharmaceuticals in a report on Friday, January 10th.
Get Our Latest Research Report on ACXP
Insider Activity at Acurx Pharmaceuticals
Hedge Funds Weigh In On Acurx Pharmaceuticals
An institutional investor recently raised its position in Acurx Pharmaceuticals stock. Prospect Financial Services LLC increased its stake in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) by 11.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 329,076 shares of the company’s stock after buying an additional 34,001 shares during the period. Prospect Financial Services LLC owned 1.93% of Acurx Pharmaceuticals worth $268,000 as of its most recent filing with the SEC. 11.53% of the stock is owned by hedge funds and other institutional investors.
Acurx Pharmaceuticals Trading Up 0.6 %
Shares of NASDAQ ACXP opened at $0.46 on Friday. The company has a market capitalization of $8.99 million, a P/E ratio of -0.42 and a beta of -1.71. Acurx Pharmaceuticals has a 12 month low of $0.43 and a 12 month high of $3.33. The stock has a 50 day moving average of $0.73 and a 200-day moving average of $1.30.
About Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
See Also
- Five stocks we like better than Acurx Pharmaceuticals
- How to Effectively Use the MarketBeat Ratings Screener
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What is MarketRank™? How to Use it
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Acurx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acurx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.